Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis
Open Access
- 21 August 2014
- journal article
- research article
- Published by Springer Nature in Glycoconjugate Journal
- Vol. 31 (6-7) , 509-521
Abstract
Glycan structure alterations during cancer regulate disease progression and represent clinical biomarkers. The study determined the degree to which changes in glycosyltransferase activities during cancer can be related to aberrant cell-surface tumor associated carbohydrate structures (TACA). To this end, changes in sialyltransferase (sialylT), fucosyltransferase (fucT) and galactosyltransferase (galT) activity were measured in normal and tumor tissue using a miniaturized enzyme activity assay and synthetic glycoconjugates bearing terminal LacNAc Type-I (Galβ1-3GlcNAc), LacNAc Type-II (Galβ1-4GlcNAc), and mucin core-1/Type-III (Galβ1-3GalNAc) structures. These data were related to TACA using tissue microarrays containing 115 breast and 26 colon cancer specimen. The results show that primary human breast and colon tumors, but not adjacent normal tissue, express elevated β1,3GalT and α2,3SialylT activity that can form α2,3SialylatedType-IIIglycans (Siaα2-3Galβ1-3GalNAc). Prostate tumors did not exhibit such elevated enzymatic activities. α1,3/4FucT activity was higher in breast, but not in colon tissue. The enzymology based prediction of enhanced α2,3sialylated Type-III structures in breast tumors was verified using histochemical analysis of tissue sections and tissue microarrays. Here, the binding of two markers that recognize Galβ1-3GalNAc (peanut lectin and mAb A78-G/A7) was elevated in breast tumor, but not in normal control, only upon sialidase treatment. These antigens were also upregulated in colon tumors though to a lesser extent. α2,3sialylatedType-III expression correlated inversely with patient HER2 expression and breast metastatic potential. Overall, enzymology measurements of glycoT activity predict truncated O-glycan structures in tumors. High expression of the α2,3sialylated T-antigen O-glycans occur in breast tumors. A transformation from linear core-1 glycan to other epitopes may accompany metastasis.Keywords
This publication has 37 references indexed in Scilit:
- α1‐3/4 fucosylation at Asn 241 of β‐haptoglobin is a novel marker for colon cancer: A combinatorial approach for development of glycan biomarkersInternational Journal of Cancer, 2011
- Systems glycobiology: biochemical reaction networks regulating glycan structure and functionGlycobiology, 2011
- The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serumGlycobiology, 2008
- Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effectsThrombosis Research, 2007
- Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats.2002
- Recombinant MUC1 Probe Authentically Reflects Cell-specific O-Glycosylation Profiles of Endogenous Breast Cancer MucinJournal of Biological Chemistry, 2002
- Tumor-Associated Carbohydrate Antigens Defining Tumor Malignancy: Basis for Development of Anti-Cancer Vaccines2001
- An 2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomasGlycobiology, 1999
- Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancerBritish Journal of Cancer, 1994
- EXPRESSION OF TN, SIALOSYL-TN, AND T-ANTIGENS IN HUMAN-COLON CANCER1989